@article{oai:nagoya.repo.nii.ac.jp:00015484,
 author = {IINUMA, MASAO and KATO, KATSUYA and AOKI, HIIZU and ANDO, KOICHI and NAKASHIMA, IZUMI and YOSHII, SAIJI},
 issue = {1-4},
 journal = {Nagoya Journal of Medical Science},
 month = {Mar},
 note = {Forty-two patients with neoplastic diseases received intravenous administration of PPD (PPD-V), and tumor markers were monitored between January, 1986 and February, 1987. Tumor markers such as CEA, AFP, SCC, CA125, IAP and polyamines decreased significantly following the PPD-V therapy. In some cases, PPD-V therapy also reduced the progression of clinical manifestation of the disease. We could not detect serum IL-2 or TNF activity. IL-2 production and sensitivity of lymphocytes were also undetectable. Intravenous administration of PPD was concluded to be effective as an adjuvant therapy against human neoplastic disease. A reduction of tumor markers was observed in 19 of the 26 assessable patients (73%). We discussed the mechanism of suppression of tumor markers by PPD-V therapy.},
 pages = {17--26},
 title = {Purified Protein Derivative (PPD) Tuberculin as a Biological Response Modifier: I. Suppression of Tumor Markers by Intravenous Administration of PPD},
 volume = {50},
 year = {1988}
}